Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Oxford Cannabinoid Technologies – executive interview

Oxford Cannabinoid Technologies – executive interview

Oxford Cannabinoid Technologies — 1 video in collection

More on this equity

Based in the UK, Oxford Cannabinoid Technologies is focused on advancing cannabinoid medicines for the treatment of pain and other indications. Lead asset OCT461201 is a CB2 selective agonist being investigated for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy and visceral pain in irritable bowel syndrome as initial pain indications. These therapies would be an alternative to opioid therapies, which have been limited in distribution in light of the opioid abuse epidemic. New drugs that target the endocannabinoid system may represent an innovative solution to address this need.

In this interview, CEO Clarissa Sowemimo-Coker provides a recap of the company’s efforts and pipeline.

< Previous
Next >

You may also be interested in these:

Healthcare

Interview with David Veitch, CEO of Basilea Pharmaceutica

Healthcare

Ultimovacs – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free